Alnylam Pharmaceuticals Interest Expense 2011-2026 | ALNY

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Alnylam Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5.2 M	-181 M	-126 M	-134 M	143 M	84.5 M	-	-	-3.02 M	6.17 M	76 K	1.82 M	-47 K	331 K	-531 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
143 M	-181 M	-15.6 M

Quarterly Interest Expense Alnylam Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.4 M	-49.7 M	-	-29.5 M	-55.7 M	-14.5 M	-	-57.7 M	-35.4 M	29 M	-	41.1 M	42.6 M	42.4 M	-	40.3 M	33.4 M	32.5 M	-	28.7 M	27.2 M	-	-	-	-	43 K	-	2.92 M	2.21 M	335 K	-	-433 K	-523 K	-2.91 M	-	401 K	229 K	5.24 M	-	-72 K	-27 K	-	-	524 K	-77 K	-82 K	-	-12 K	-11 K	5 K	-	-3 K	-21 K	191 K	-	-597 K	-16 K	81 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
42.6 M	-57.7 M	1.89 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Nanobiotix S.A. NBTX	-4.68 M	$ 30.34	-0.82 %	$ 286 B	France
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Akebia Therapeutics AKBA	58 K	$ 1.4	-0.71 %	$ 360 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	14.2 M	$ 95.5	3.83 %	$ 27.2 B	Germany
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.92	-0.34 %	$ 6.35 B	Israel
Aytu BioScience AYTU	-512 K	$ 2.55	-0.78 %	$ 16 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 20.37	-2.4 %	$ 952 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.08	-2.16 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.21	-1.47 %	$ 3.08 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Celldex Therapeutics CLDX	927 K	$ 32.24	-4.1 %	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Cabaletta Bio CABA	2 M	$ 3.13	-1.26 %	$ 315 M	USA
Codiak BioSciences CDAK	2.7 M	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
InflaRx N.V. IFRX	2.69 K	$ 1.0	-2.91 %	$ 152 M	Germany
Immutep Limited IMMP	8.2 K	$ 0.31	-2.52 %	$ 1.08 B	Australia
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Concert Pharmaceuticals CNCE	-309 K	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	100 K	$ 3.83	-2.3 %	$ 258 B	Britain
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Celsion Corporation CLSN	5.03 M	-	-6.63 %	$ 13.9 M	USA